The so far preliminary data shows that the low metastatic risk PC patients could benefit from GRPr targeting while in high-risk patients the PSMA-based radiotracers could serve as a valuable tool (Minamimoto et al. 2016). Here, GRPR is linked to pachyonychia congenita.